ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

▤ Summary

ITM announced Phase 3 COMPETE quality-of-life results for its investigational radiopharmaceutical ITM-11 at ASCO 2026. The data showed that patients receiving n.c.a. Lu-edotreotide maintained quality of life better than those on everolimus. Patients on ITM-11 also had a longer median time before quality of life deteriorated and a higher rate of meaningful improvement. The company says these findings add patient-centered evidence to the previously reported efficacy data in GEP-NETs. ITM continues to advance ITM-11 and other radiopharmaceutical programs across its oncology pipeline.

▦ Linked Companies